Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight<sup>®</sup>) in previously treated patients with severe haemophilia A: interim results of the guardian<sup>™</sup>2 extension trial
Haemophilia